HORIZON 2020 dedicated SME instrument
In 2015 Biovica received a Horizon 2020 SME-grant (Phase 2)
Over 600 small and medium-sized enterprises (SME) applied for Horizon SME 2020-grants in 2014. After thorough evaluation, less than 10 % got support for their projects.
In September 2015 Biovica was granted 682 000 € for a six year project. The grant supports the Clinical validation of the DiviTum assay in two high profile clinical studies in Europe.
Small and medium enterprises can engage in collaborative projects and they are supported through a Horizon 2020 dedicated SME instrument designed specifically for highly innovative smaller companies.
The support is targeted to bridge the gap between research and the market by helping innovative enterprise to develop their technological breakthroughs into viable products with real commercial potential.
Support is provided in three different stages covering the whole innovation cycle as follows:
- Phase 1 feasibility for assessment of the technological and commercial potential of a project (proof of concept).
- Phase 2 innovation focusing on activities such as demonstration, testing, prototyping, pilot lines, scale-up studies, miniaturization, design, performance verification etc. and market replication
- Phase 3 commercialization focusing on bringing the products to the markets
Biovica’s mission – more informed treatment decisions
The traditionally practiced approach to cancer therapy and development of new cancer drugs is to treat a large pool of patients as potential responders. This results in patients not receiving the optimal treatment; payers paying for treatments that do not benefit patients; drug developers facing higher risk of regulatory failure due to not being able to use better tools for selection of patients in the clinical development program; and clinicians lacking predictive and monitoring tools to administer optimal treatment of patients.
Biovica has developed a state-of-the-art assay kit – DiviTum®, for the serum-based detection of Thymidine Kinase (TK) activity – a key enzyme involved in cell proliferation. There is compelling scientific rationale to use TK as a biomarker for drugs that disrupt cell cycle regulation, such as Cyclin Dependent Kinase (CDK) inhibitors.
As part of the previously conducted SME Instrument Phase 1 feasibility study, our company has identified the clinical study & research market segment, comprised of pharma companies that develop CDK inhibitors, as a current target for the commercialization of DiviTum.
Our company has successfully negotiated to be part of two high-profile clinical studies involving a novel CDK inhibitor with leading oncology institutes in Europe. A clinically validated DiviTum has the potential to become the gold standard predictive and efficacy biomarker for cell cycle regulating drugs in selected advanced, solid tumors. This will benefit patients through improved utilization of current and novel treatments; payers by saving costs on ineffective treatments; clinicians by providing a critical clinical decision tool; and drug developers by improving clinical trial success rates through optimized cohort selection, shorter time to market and decreased risk of regulatory failure.
Link to press release
About Horizon 2020 – The EU Framework Program for Research and Innovation
Horizon 2020 is the biggest EU Research and Innovation program ever with nearly €80 billion of funding available over 7 years (2014 to 2020) – in addition to the private investment that this money will attract. It promises more breakthroughs, discoveries and world-firsts by taking great ideas from the lab to the market. The goal is to ensure Europe produces world-class science, removes barriers to innovation and makes it easier for the public and private sectors to work together in delivering innovation.